Newsletter

Hello Valued VIP Subscribers

Hello members,

We have an jam packed week this week and we are ready to kick it off with CBIS!

CBIS announced last week that they have signed an agreement with a major IR firm to help them spread the word about CBIS!

Trading at just .02 these levels may not last!

Last have a good day folks!

-----------------------------

It's time to bring CBIS into the spot light!

With Thanksgiving nearly upon us we want to make next week a special one!

CBIS is in the biggest growing medical industry thus far; cannibas and all it's postive medical abilities are taking the world by storm!

Not only is this a multi-billion dollar industry, it's become and WORLD industry.

The chart on CBIS is screaming UP and we aim to be there for the ride.

The Science of Cannabinoids

Cannabinoids have an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

Some applications of cannabinoids have been well established in peer-reviewed literature such as alleviating nausea and stimulating the appetite for people with AIDS and Cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its perceived effectiveness in alleviating certain autoimmune disorders, such as Crohn’s Disease.

Our team of scientists will produce and commercialize products derived from cannabis-based botanical extracts. Even today, new uses for cannabinoids are consistently discovered. For example, scientists recently found that topical cannabinoid-based preparations can be effective against MRSI, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments.

In 2001, an article published in the Canadian Medical Association Journal revealed that, based on self-identified needs, it is estimated that 2% (or 400,000) of Canadian adults were already utilizing cannabinoids for medical purposes. With ever increasing use and scientific support for cannabinoid medicines occurring in the US and around the world, we are looking at a new multi-billion dollar industry that will play a dramatic role that will impact human health on a global scale.

Corporate Overview

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are cGMP compliant, surpassing high quality standard industrial and food processing requirements.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.

Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.

In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders" (CS-NEURO-1). The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders.

Basis & Philosophy

Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

Some key phytocannabinoids are:

tetrahydrocannabinol (THC)cannabidiol (CBD)cannabigerol (CBG)cannabichromene (CBC)cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.

We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.

Our products, broadly described, are medical cannabinoid products developed from one or more of the cannabinoid compounds found in the cannabis plant.

Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.

The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.

Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabinoids had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.

There are three general types of cannabinoids:

1. Phytocannabinoids, that occur uniquely in the cannabis plant.
2. Endogenous cannabinoids produced naturally in many animal species including humans.
3. Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.

Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.

Cannabinoid receptors in the human body were not discovered until 1988. CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.

CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.

The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.

Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson's, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.

Cannabinoids have been used medicinally for thousands of years in China, India, and the Middle East. Of course, most traditional medicines were plant-based, but until recently no one knew how or why they worked. Though cannabinoids are a very old form of medication, we are inspired by this "folk medicine," whose efficacy modern science now routinely verifies, and we are capable of creating systematic and effective use of cannabinoid therapies.

While cannabinoids were widely used in the West during the 19th century, the technology was lacking to detect and understand its active ingredients, to standardize dosages of those ingredients, and to effectively deliver those ingredients, owing largely to cannabinoids' non-water-solubility. Consequently, it became less widely used in the early 20th century and was eventually renamed "marijuana". It was gradually removed from the pharmacopeiae of most advanced countries; and research was discouraged.

Remember, we always encourage you to do further research. Never take our word for it, read our disclaimer to see why, and of course always consult a professional.

Just because a situation looks great things can still go wrong and often do. Be smart and protect yourself.

Enjoy your evening,

Remember to insure timely delivery please add our email (info@vippennystocksite.com) to your safe senders contacts.  We would hate for you to not receive the alert on time or not at all. 

PLEASE NOTE WELL: Vippennystocksite.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. VIPPENNYSTOCKSITE.COM WILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at VIPPENNYSTOCKSITE.COM &/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

*Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.*

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe at any time.

We have been compensated up to 3.thousand cash dollars via an un-affiliated 3rd party for this profile of CBIS.

Releaseof Liability: Through use of this email and/or website advertisement viewing or using you agree to hold Vippennystocksite.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Vippennystocksite.com sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Vippennystocksite.com or an offer or solicitation to buy or sell any security. 

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Vippennystocksite.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Vippennystocksite.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, Vippennystocksite.com has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Vippennystocksite.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Vippennystocksite.com is compliant with the Can Spam Act of 2003. Vippennystocksite.com does not offer such advice or analysis, and Vippennystocksite.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage. 

In preparing this publication, Vippennystocksite.com has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Vippennystocksite.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Vippennystocksite.com is not responsible for any claims made by the companies advertised herein, nor is Vippennystocksite.com responsible for any other promotional firm, its program or its structure.